Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07067099
Starting soon Phase 1

Neutralizing Interferon Type 1 in Hidradenitis Suppurativa

NCT07067099 · tracked via the Priya Life Science France tracker
Sponsor
Centre Hospitalier Universitaire de Besancon
Phase
Phase 1
Started
2025-09
Last updated
2025-07-16

Condition(s) studied

Hidradenitis Suppurativa (HS)

Investigational drug(s) / intervention(s)

Plasma with neutralizing autoantibodies to Type I Interferons

Plasma with neutralizing autoantibodies to Type I Interferons: Transfusion of one unit of plasma containing high titre anti-IFN-1 autoantibodies

Study summary

The purpose of the study is to evaluate the safety and type 1 Interferon (IFN) neutralization in patients with refractory severe Hidradenitis Suppurativa (Hurley stage III) after transfusion of plasma containing high titer anti-IFN-1 autoantibodies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men and women aged over 18 * Patients with Hidradenitis suppurativa (Hurley stages II-III) * Disease affecting at least two distinct anatomical areas, * Total count of abscesses (A) and inflammatory nodules (N) ≥ 3 * IHS4 score ≥ 11 * Treatment of pain with opioids (≥ 20 mg/day) * Resistance to previous use (for at least 3 months) of systemic antibiotics and TNF inhibitors (infliximab or adalimumab) or anti-IL17 (secukinumab). * Vaccinations against SARS-CoV-2 and influenza up to date (or able to be carried out prior to the study procedure) * Women using an effective method of contraception * Signed informed consent Exclusion Criteria: * Active viral infection: herpes, VZV, HIV, HBV, HCV * Active bacterial infection requiring systemic antibiotics * Known allergy to blood components/plasma proteins * Poor myocardial function (increased risk of for transfusion-associated circulatory overload) (symptomatic left ventricular failure and ejection fraction \< 40%) * Pregnant women * Subjects with no social security coverage

Primary outcome measure(s)

  • Safety of transfusion of plasma containing high titer anti-IFN-1 auto-Antibodies — within 28 days of infusion
    Two aspects are considered when assessing safety: * Immediate serious adverse events (SAEs) (within 24 hours of infusion) and, * Delayed SAEs (within 28 days of infusion). Adverse events are coded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE V5.0).

Trial sites (1)

FacilityCityRegionStatus
CHU Besançon Besançon France

More Centre Hospitalier Universitaire de Besancon trials in France

Exploratory Study of the Relevance of a Blood Test in the Management of Patients in the Context of Colorectal Cancer Screening Recruiting
Post Intensive Care Unit Atrial Fibrillation Recruiting
Adverse Drug Events in Patients on Oral Anticoagulation in the Emergency Department Recruiting
Study of Emotional Regulation and Underlying Prefrontal Activity in Binge Eating Disorder Recruiting
Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease Recruiting

Other trials for the same condition

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib Recruiting
MAIT Cells in Hidradenitis Suppurativa Starting soon
FEcal tranSplantation in HidradeniTIs suppuratiVA : a piLot Study Starting soon
A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07067099 on ClinicalTrials.gov ↗ ← All trials in France